MIM
VRTX icon

MTM Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

MTM Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.2K Hold
117
– – 0.02% 321
2025
Q4 		$53K Hold
117
– – 0.02% 325
2025
Q3 		$45.8K Hold
117
– – 0.01% 346
2025
Q2 		$52.1K Buy
+117
New +$53.9K 0.02% 332

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MTM Investment Management's VRTX Position: Q1 2026 in Review

MTM Investment Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 117 shares worth $52.2K. The position accounts for 0.02% of the portfolio, ranked #321.

MTM Investment Management first reported a position in VRTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $53K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • MTM Investment Management held 117 shares of Vertex Pharmaceuticals worth $52.2K as of Q1 2026.
  • MTM Investment Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.02% of MTM Investment Management's portfolio in Q1 2026, its #321 holding.
  • MTM Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • MTM Investment Management's Vertex Pharmaceuticals position peaked at $53K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on MTM Investment Management's 13F filing for Q1 2026, filed 6 May 2026.